Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4128358 | 1.00 | GAA (0.43) | GAAHPGDCCR1KMT2ACNR1 | |
| SCHEMBL4140486 | 0.89 | CCR1 (0.49) | CCR1KMT2ACNR1CNR2ALDH1A1 | |
| SCHEMBL4140483 | 0.86 | CCR1 (0.41) | GAACCR1KMT2ACNR1CNR2 | |
| SCHEMBL4141073 | 0.84 | POLB (0.39) | GAACCR1KMT2ACNR1CNR2 | |
| SCHEMBL4141078 | 0.84 | POLB (0.39) | GAACCR1KMT2ACNR1CNR2 | |
| SCHEMBL4136813 | 0.82 | TRPV4 (0.40) | GAAHPGDCCR1ALDH1A1 | |
| SCHEMBL13872501 | 0.79 | CCR1 (0.48) | GAAHPGDCCR1KMT2ACNR1 | |
| SCHEMBL4135431 | 0.78 | TRPV4 (0.41) | GAAKMT2AALDH1A1NPSR1 | |
| SCHEMBL4136055 | 0.77 | GAA (0.40) | GAAHPGDCCR1CNR1CNR2 | |
| SCHEMBL4773183 | 0.77 | GAA (0.40) | GAAHPGDCCR1CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | claimed |
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
| WO-2007030761-A2 | ACYCLIC 1,4-DIAMINES AND USES THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | TRPV4, TRPC4, TRPV1 | GAA 3715/4885HPGD 1044/4885CCR1 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.